Nordic Nanovector to present at 11[th] Annual World ADC Europe 2021 Digital

Report this content

Oslo, Norway, 8 March 2020

Nordic Nanovector ASA (OSE: NANOV) announces that its Chief Scientific Officer, Jostein Dahle, will give a presentation on 9 March at the 11th Annual World ADC Europe 2021 Digital event (8-11 March 2021) in the Discovery stream discussing the question: Should Payloads be Super-Potent?

Presentation details are as follows:

Title: Targeting CD37 with Alpha- & Beta-Emitting Radioimmunoconjugates

Date/time: Tuesday, 9 March 2021 at 11:40am GMT

During his presentation, Dr Dahle with cover the following points:

  • Review CD37 as target for radioimmunotherapy
  • Analyse preclinical and clinical data for treatment of Non-Hodgkin’s Lymphoma (NHL) with the beta-emitting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®)
  • Evaluate preclinical data for treatment of Chronic Lymphocytic Leukaemia and NHL with the alpha-emitting radioimmunoconjugate 212Pb-TCMC-NNV003 (Alpha37)

World ADC Europe is an industry-leading conference and Europe’s largest gathering of ADC stakeholders. It brings together 300 drug developers from 160 active ADC organisations to help forward-thinking researchers from the pharmaceutical, biotech and academic community advance the development of antibody-drug conjugates.

For further information, please contact:                            

IR enquiries

Malene Brondberg, CFO
Cell: +44 7561 431 762

Media Enquiries

Mark Swallow/Frazer Hall/David Dible (Citigate Dewe Rogerson)
Tel: +44 203 926 8535

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.

Further information can be found at